In the Phase I study, eloralintide led to body weight reductions of up to 11.3% over just 12 weeks in individuals with obesity, demonstrating early efficacy that aligns with emerging expectations for amylin-based therapies.
Ongoing trials evaluating the therapy both as a monotherapy and in combination with GLP-1 drug (tirzepatide) will decide the real successor of tirzepatide
At the American Diabetes Association (ADA) 2025 Scientific Sessions, Eli Lilly unveiled encouraging Phase I data for its investigational amylin analog, eloralintide, positioning the agent as a promising next-generation therapy for obesity. The trial, which enrolled 100 participants across...
